SPR720 is a broad spectrum, oral candidate that, if approved, would be a once daily oral treatment for patients with NTM-PD.
Learn more at
You are now leaving the site.
You are leaving www.sperotherapeutics.com
Please note that Spero Therapeutics, Inc. is not responsible for the content or services of that site or any further links from that site. Spero Therapeutics, Inc. is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement of the linked site or its content by Spero Therapeutics, Inc. Please be aware that the linked site may be governed by its own set of terms and conditions and privacy policy, for which Spero Therapeutics, Inc. has no responsibility.
Do you wish to continue in a new tab?
Understanding NTM-PD Infections and Their Impact
NTM-PD, also known as NTM lung disease, is caused by bacteria naturally found in soil, dust, and water. These bacteria belong to the Mycobacterium family, excluding those that cause tuberculosis and leprosy. The most common cause of NTM-PD infections is the Mycobacterium avium complex (MAC).
A Dire Need for Antibiotic Resistance Solutions
Multidrug-resistant (MDR) bacterial infections are becoming increasingly common in the hospital and community setting, emphasizing the need for new orally administered and intravenous (IV) antibiotics that can effectively and safely treat such infections. Spero Therapeutics seeks to address these unmet needs.
